Sigma Planning Corp Raises Stock Holdings in Pfizer Inc. (NYSE:PFE)

Sigma Planning Corp raised its position in Pfizer Inc. (NYSE:PFE - Free Report) by 18.8% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 180,092 shares of the biopharmaceutical company's stock after acquiring an additional 28,562 shares during the quarter. Sigma Planning Corp's holdings in Pfizer were worth $4,564,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. Catalyst Financial Partners LLC grew its position in shares of Pfizer by 13.5% during the first quarter. Catalyst Financial Partners LLC now owns 19,874 shares of the biopharmaceutical company's stock worth $504,000 after purchasing an additional 2,358 shares in the last quarter. Signaturefd LLC grew its position in shares of Pfizer by 11.9% during the first quarter. Signaturefd LLC now owns 89,077 shares of the biopharmaceutical company's stock worth $2,257,000 after purchasing an additional 9,454 shares in the last quarter. Edgestream Partners L.P. grew its position in shares of Pfizer by 612.7% during the first quarter. Edgestream Partners L.P. now owns 342,794 shares of the biopharmaceutical company's stock worth $8,686,000 after purchasing an additional 294,696 shares in the last quarter. Leelyn Smith LLC grew its position in shares of Pfizer by 6.7% during the first quarter. Leelyn Smith LLC now owns 93,608 shares of the biopharmaceutical company's stock worth $2,372,000 after purchasing an additional 5,841 shares in the last quarter. Finally, Mitchell Mcleod Pugh & Williams Inc. grew its position in shares of Pfizer by 4.0% during the first quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 34,457 shares of the biopharmaceutical company's stock worth $873,000 after purchasing an additional 1,331 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Down 0.1%

PFE traded down $0.02 during trading hours on Thursday, reaching $24.59. 47,333,190 shares of the company's stock traded hands, compared to its average volume of 41,969,333. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm has a 50-day moving average price of $23.99 and a 200 day moving average price of $24.77. The firm has a market capitalization of $139.83 billion, a PE ratio of 17.82, a PEG ratio of 0.90 and a beta of 0.58. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. Pfizer's revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.82 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.99%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is currently 124.64%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Leerink Partners reduced their price objective on Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research note on Wednesday, April 30th. Citigroup increased their target price on Pfizer from $23.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Bank of America increased their target price on Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Wolfe Research increased their target price on Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a research report on Wednesday, April 30th. Finally, TD Cowen lowered their target price on Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research report on Tuesday, April 22nd. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat, Pfizer has an average rating of "Hold" and an average target price of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.